

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number  
**WO 2004/076623 A2**

(51) International Patent Classification<sup>7</sup>: **C12N**  
(21) International Application Number:  
PCT/JP2004/002446  
(22) International Filing Date: 27 February 2004 (27.02.2004)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
60/450,644 28 February 2003 (28.02.2003) US

(71) Applicants (for all designated States except US): **ONCOTHERAPY SCIENCE, INC.** [JP/JP]; 3-16-13, Shirokanedai, Minato-ku, Tokyo, 1080071 (JP). **JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO** [JP/JP]; 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo, 1138654 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NAKAMURA, Yusuke** [JP/JP]; 17-33, Azamino 1-chome, Aoba-ku, Yokohama-shi, Kanagawa, 2250011 (JP). **FURUKAWA, Yoichi** [JP/JP]; 10-40, Miyazaki 3-chome, Miyamae-ku, Kawasaki-shi Kanagawa, 2160033 (JP).

(74) Agents: **SHIMIZU, Hatsushi et al.**; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS OF INHIBITING CELL GROWTH

(57) Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.

WO 2004/076623 A2

- 1 -

## DESCRIPTION

## COMPOSITIONS AND METHODS OF INHIBITING CELL GROWTH

5 Technical Field

The present invention relates to the field of biological science, more specifically to the field of cancer research. In particular, the present invention relates a composition comprising a ZNFN3A1 small interfering RNA (siRNA).

10 Background Art

Hepatocellular carcinoma (HCC) is among the five most frequent cancers and is the fourth leading cause of cancer death in the world. Although recent medical advances have made great progress in diagnosing the disease, a large number of patients with HCCs are still diagnosed at advanced stages. Most of the patients are not cured by surgical resection because of severe liver dysfunction, widespread and/or multiple tumors, or high incidence of recurrence. Therefore development of highly effective chemotherapeutic drugs and preventive strategies are matters of pressing concern.

Disclosure of the Invention

20 The present invention based on the surprising discovery that small interfering RNAs (siRNAs) selective for ZNFN3A1 are effective for inhibiting the cellular growth of various cancer cells, including those involved in HCC.

The invention provides methods for inhibiting cell growth. Among the methods provided are those comprising contacting a cell with a composition comprising a ZNFN3A1 small interfering RNA (siRNA). The invention also provides methods for inhibiting tumor cell growth in a subject. Such methods include administering to a subject a composition comprising a ZNFN3A1 small interfering RNA (siRNA). Another aspect of the invention provides methods for inhibiting the expression of the ZNFN3A1 gene in a cell of a biological sample. Expression of the gene may be inhibited by introduction of a double stranded ribonucleic acid (RNA) molecule into the cell in an amount sufficient to inhibit expression of the ZNFN3A1 gene. Another aspect of the invention relates to products including nucleic acid sequences and vectors as well as to compositions

- 2 -

comprising them, useful, for example, in the provided methods. Among the products provided are siRNA molecules having the property to inhibit expression of the ZNFN3A1 gene when introduced into a cell expressing said gene. Among such molecules are those that comprise a sense strand and an antisense strand, wherein the sense strand comprises a  
5 ribonucleotide sequence corresponding to a ZNFN3A1 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand. The sense and the antisense strands of the molecule hybridize to each other to form a double-stranded molecule.

As used herein, the term "organism" refers to any living entity comprised of at least  
10 one cell. A living organism can be as simple as, for example, a single eukaryotic cell or as complex as a mammal, including a human being.

As used herein, the term "biological sample" refers to a whole organism or a subset of its tissues, cells or component parts (e.g. body fluids, including but not limited to blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic  
15 cord blood, urine, vaginal fluid and semen). "Biological sample" further refers to a homogenate, lysate, extract, cell culture or tissue culture prepared from a whole organism or a subset of its cells, tissues or component parts, or a fraction or portion thereof. Lastly, "biological sample" refers to a medium, such as a nutrient broth or gel in which an organism has been propagated, which contains cellular components, such as proteins or  
20 polynucleotides.

The invention features methods of inhibiting cell growth. Cell growth is inhibited by contacting a cell with a composition of a ZNFN3A1 small interfering RNA (siRNA). ZNFN3A1 is a zinc finger protein that is overexpressed in tumors such as hepatocellular carcinoma or colorectal adenocarcinoma. Growth of the cell expressing ZNFN3A1 can be  
25 inhibited by the present invention. The cell is further contacted with a transfection-enhancing agent. The cell is provided *in vitro*, *in vivo* or *ex vivo*. The subject is a mammal, e.g., a human, non-human primate, mouse, rat, dog, cat, horse, or cow. The cell is a hepatic cell or a colon cell. Alternatively, the cell is a tumor cell ( *i.e.*, cancer cell) such as a colorectal cancer cell or a liver cancer cell. For example, the cell is a colorectal  
30 adenocarcinoma cell or a hepatocellular carcinoma cell. By inhibiting cell growth is meant that the treated cell proliferates at a lower rate or has decreased viability than an untreated cell. Cell growth is measured by proliferation assays known in the art.

- 3 -

By the term "siRNA" is meant a double stranded RNA molecule which prevents translation of a target mRNA. Standard techniques of introducing siRNA into the cell are used, including those in which DNA is a template from which RNA is transcribed. The siRNA includes a sense ZNFN3A1 nucleic acid sequence, an anti-sense ZNFN3A1 nucleic acid sequence or both. The siRNA is constructed such that a single transcript has both the sense and complementary antisense sequences from the target gene, *e.g.*, a hairpin.

The method is used to alter gene expression in a cell in which expression of ZNFN3A1 is upregulated, *e.g.*, as a result of malignant transformation of the cells. Binding of the siRNA to an ZNFN3A1 transcript in the target cell results in a reduction in ZNFN3A1 production by the cell. The length of the oligonucleotide is at least 10 nucleotides and may be as long as the naturally-occurring ZNFN3A1 transcript. Preferably, the oligonucleotide is 19-25 nucleotides in length. Most preferably, the oligonucleotide is less than 75, 50, or 25 nucleotides in length. Examples of ZNFN3A1 siRNA oligonucleotides which inhibit ZNFN3A1 expression in mammalian cells include oligonucleotides containing target sequences, for example, nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1.

Methods for designing double stranded RNA having the ability to inhibit gene expression in a target cell are known. (See for example, US Patent No. 6,506,559, herein incorporated by reference in its entirety). For example, a computer program for designing siRNAs is available from the Ambion website ([http://www.ambion.com/techlib/misc/siRNA\\_finder.html](http://www.ambion.com/techlib/misc/siRNA_finder.html)).

The computer program selects nucleotide sequences for siRNA synthesis based on the following protocol.

#### Selection of siRNA Target Sites

1. Beginning with the AUG start codon of the transcript, scan downstream for AA dinucleotide sequences. Record the occurrence of each AA and the 3' adjacent 19 nucleotides as potential siRNA target sites. Tuschl et al. recommend against designing siRNA to the 5' and 3' untranslated regions (UTRs) and regions near the start codon (within 75bases) as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex.



- 4 -

2. Compare the potential target sites to the appropriate genome database (human, mouse, rat, etc.) and eliminate from consideration any target sequences with significant homology to other coding sequences. We suggest using BLAST, which can be found on the NCBI server at: [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)
- 5 3. Select qualifying target sequences for synthesis. Selecting several target sequences along the length of the gene to evaluate is typical.

Also included in the invention are isolated polynucleotides that include the nucleic acid sequence of target sequences, for example, nucleotides 451-471 (SEQ ID NO:58), 532-552 (SEQ ID NO:60), 623-643 (SEQ ID NO:61), 625-645 (SEQ ID NO:62), 636-656 (SEQ ID NO:63), 726-746 (SEQ ID NO:64), 923-943 (SEQ ID NO:66), 1065-1085 (SEQ ID NO:68), and 1258-1278 (SEQ ID NO:69) of SEQ ID NO:1 or a polynucleotide that is complementary to the nucleic acid sequence of nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1. As used herein, an "isolated nucleic acid" is a nucleic acid removed from its original environment (e.g., the natural environment if naturally occurring) and thus, synthetically altered from its natural state. In the present invention, isolated nucleic acid includes DNA, RNA, and derivatives thereof. When the isolated nucleic acid is RNA or derivatives thereof, base "t" should be replaced with "u" in the nucleotide sequences. As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a polynucleotide, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Complementary nucleic acid sequences hybridize under appropriate conditions to form stable duplexes containing few or no mismatches. Furthermore, the sense strand and antisense strand of the isolated nucleotide of the present invention, can form double stranded nucleotide or hairpin loop structure by the hybridization. In a preferred embodiment, such duplexes contain no more than 1 mismatch for every 10 matches. In an especially preferred embodiment, where the strands of the duplex are fully complementary, such duplexes contain no mismatches. The polynucleotide is less than 1622 nucleotides in length. For example, the polynucleotide is less than 500, 200, or 75 nucleotides in length. Also included in the invention is a vector containing one or more of the nucleic acids described herein, and a cell containing the

- 5 -

vectors. The isolated nucleic acids of the present invention are useful for siRNA against ZNFN3A1 or DNA encoding the siRNA. When the nucleic acids are used for siRNA or coding DNA thereof, the sense strand is preferably longer than 19 nucleotides, and more preferably longer than 21 nucleotides.

5 The invention is based in part on the discovery that the gene encoding a zinc finger protein, ZNFN3A1 is overexpressed in hepatocellular carcinoma (HCC) compared to non-cancerous liver tissue. The ZNFN3A1 cDNA is 1622 nucleotides in length. The 1284 ORF encodes a 428-amino acid protein with a zinc finger motif. The nucleic acid and polypeptide sequences of ZNFN3A1 are shown in Tables 1 and 2. In Table 1, the 5' and 3' untranslated region is shown in *italic*, the start and stop codons are in **bold**. The subcellular localization of ZNFN3A1 protein is altered during cell cycle progression and by the density of cultured cells. ZNFN3A1 protein accumulates in the nucleus when cells are in middle to late S phase or cultured in sparse conditions. Whereas, ZNFN3A1 protein localizes in the cytoplasm as well as in the nucleus when cells are in other phases of the cell cycle or grown in a dense condition. ZNFN3A1 forms a ternary complex with KIAA0054 protein and RNA polymerase II *in vivo*, which activates transcription of downstream genes including epidermal growth factor receptor (*EGFR*) through a direct binding of the complex with an element of "5'-CCCTCC-3'" in the 5' flanking region.

Table 1 Nucleic Acid Sequence of ZNFN3A1 (SEQ ID No:1)

<i>gtgcgcgcag</i>	<i>ggcgcaggcg</i>	<i>cgcggggtccc</i>	<i>ggcagcccg</i>	<i>gagacgccc</i>	<i>ctgctggacg</i>	60
<i>cggttagccg</i>	<i>tctgaggtgc</i>	<i>cggagctgcg</i>	<i>ggagg</i>	<b>atg</b>	<i>gag ccg ctg aag gtg</i>	113
<i>gaa aag ttc</i>	<i>gca acc gcc aac agg gga aac ggg</i>	<i>ctg cgc gcc gtg acc</i>				161
<i>ccg ctg cgc</i>	<i>ccc gga gag cta ctc ttc cgc tgc gat</i>	<i>ccc ttg gcg tac</i>				209
<i>acg gtg tgc</i>	<i>aag ggg agt cgt ggc gtc gtc tgc gac</i>	<i>cgc tgc ctt ctc</i>				257
<i>ggg aag gaa aag</i>	<i>ctg atg cga tgc tct cag tgc cgc gtc gcc</i>	<i>aaa tac</i>				305
<i>tgt agt gct aag</i>	<i>tgt cag aaa aaa gct tgg cca gac cac</i>	<i>aag cgg gaa</i>				353
<i>tgc aaa tgc ctt</i>	<i>aaa agc tgc aaa ccc aga tat cct cca gac</i>	<i>tcc gtt</i>				401
<i>cga ctt ctt ggc</i>	<i>aga gtt gtc ttc aaa ctt atg gat gga gca</i>	<i>cct tca</i>				449
<i>gaa tca gag aag</i>	<i>ctt tac tca ttt tat gat ctg gag tca aat</i>	<i>att aac</i>				497
<i>aaa ctg act gaa</i>	<i>gat aag aaa gag ggc ctc agg caa ctc gta</i>	<i>atg aca</i>				545
<i>ttt caa cat ttc</i>	<i>atg aga gaa gaa ata cag gat gcc tct cag</i>	<i>ctg cca</i>				593
<i>cct gcc ttt gac</i>	<i>ctt ttt gaa gcc ttt gca aaa gtg atc</i>	<i>tgc aac tct</i>				641
<i>ttc acc atc tgt</i>	<i>aat gcg gag atg cag gaa gtt ggt gtt ggc</i>	<i>cta tat</i>				689
<i>ccc agt atc tct</i>	<i>ttg ctc aat cac agc tgt gac ccc aac</i>	<i>tgt tgc att</i>				737
<i>gtg ttc aat ggg</i>	<i>ccc cac ctc tta ctg cga gca gtc cga gac</i>	<i>atc gag</i>				785
<i>gtg gga gag gag</i>	<i>ctc acc atc tgc tac ctg gat atg ctg</i>	<i>atg acc agt</i>				833
<i>gag gag cgc cgg</i>	<i>aag cag ctg agg gac cag tac tgc ttt</i>	<i>gaa tgt gac</i>				881
<i>tgt ttc cgt tgc</i>	<i>caa acc cag gac aag gat gct gat atg</i>	<i>cta act ggt</i>				929
<i>gat gag caa gta</i>	<i>tgg aag gaa gtt caa gaa tcc ctg</i>	<i>aaa aaa att gaa</i>				977
<i>gaa ctg aag gca</i>	<i>cac tgg aag tgg gag cag gtt ctg gcc</i>	<i>atg tgc cag</i>				1025
<i>gcg atc ata agc</i>	<i>agc aat tct gaa cgg ctt ccc gat</i>	<i>atc aac atc tac</i>				1073
<i>cag ctg aag gtg</i>	<i>ctc gac tgc gcc atg gat gcc tgc</i>	<i>atc aac ctc ggc</i>				1121
<i>ctg ttg gag gaa</i>	<i>gcc ttg ttc tat ggt act cgg acc</i>	<i>atg gag cca tac</i>				1169
<i>agg att ttt ttc</i>	<i>cca gga agc cat ccc gtc aga ggg</i>	<i>ggt caa gtg atg</i>				1217

- 6 -

aaa gtt ggc aaa ctg cag cta cat caa ggc atg ttt ccc caa gca atg	1265
aag aat ctg aga ctg gct ttt gat att atg aga gtg aca cat ggc aga	1313
gaa cac agc ctg att gaa gat ttg att cta ctt tta gaa gaa tgc gac	1361
gcc aac atc aga gca tcc taa gggaaacgcag tcagaggggaa atacggcgtg	1412
tgtctttgtt gaatgcctta ttgaggtcac acactctatg ctttgtttagc tgtgtgaacc	1472
tctcttattg gaaattctgt tccgtgtttg tgtaggtataa taaaggcaga catggtttgc	1532
aaaccacaag aatcattagt tgtagagaag cagcattata ataaattcaa aacatttggt	1592
tgaggatgcc aaaaaaaaaa aaaaaaaaaa	1622

Table 2 Polypeptide Sequence of ZNFN3A1 (SEQ ID NO:2)

Met	Glu	Pro	Leu	Lys	Val	Glu	Lys	Phe	Ala	Thr	Ala	Asn	Arg	Gly	Asn	
1				5					10					15		
Gly	Leu	Arg	Ala	Val	Thr	Pro	Leu	Arg	Pro	Gly	Glu	Leu	Leu	Phe	Arg	
			20					25					30			
Ser	Asp	Pro	Leu	Ala	Tyr	Thr	Val	Cys	Lys	Gly	Ser	Arg	Gly	Val	Val	
		35					40					45				
Cys	Asp	Arg	Cys	Leu	Leu	Gly	Lys	Glu	Lys	Leu	Met	Arg	Cys	Ser	Gln	
	50					55					60					
Cys	Arg	Val	Ala	Lys	Tyr	Cys	Ser	Ala	Lys	Cys	Gln	Lys	Lys	Ala	Trp	
65					70					75					80	
Pro	Asp	His	Lys	Arg	Glu	Cys	Lys	Cys	Leu	Lys	Ser	Cys	Lys	Pro	Arg	
			85					90						95		
Tyr	Pro	Pro	Asp	Ser	Val	Arg	Leu	Leu	Gly	Arg	Val	Val	Phe	Lys	Leu	
			100					105					110			
Met	Asp	Gly	Ala	Pro	Ser	Glu	Ser	Glu	Lys	Leu	Tyr	Ser	Phe	Tyr	Asp	
	115						120					125				
Leu	Glu	Ser	Asn	Ile	Asn	Lys	Leu	Thr	Glu	Asp	Lys	Lys	Glu	Gly	Leu	
	130					135					140					
Arg	Gln	Leu	Val	Met	Thr	Phe	Gln	His	Phe	Met	Arg	Glu	Glu	Ile	Gln	
145					150				155						160	
Asp	Ala	Ser	Gln	Leu	Pro	Pro	Ala	Phe	Asp	Leu	Phe	Glu	Ala	Phe	Ala	
			165					170						175		
Lys	Val	Ile	Cys	Asn	Ser	Phe	Thr	Ile	Cys	Asn	Ala	Glu	Met	Gln	Glu	
		180					185						190			
Val	Gly	Val	Gly	Leu	Tyr	Pro	Ser	Ile	Ser	Leu	Leu	Asn	His	Ser	Cys	
	195					200						205				
Asp	Pro	Asn	Cys	Ser	Ile	Val	Phe	Asn	Gly	Pro	His	Leu	Leu	Leu	Arg	
	210				215					220						
Ala	Val	Arg	Asp	Ile	Glu	Val	Gly	Glu	Glu	Leu	Thr	Ile	Cys	Tyr	Leu	
225				230				235							240	

- 7 -

Asp	Met	Leu	Met	Thr	Ser	Glu	Glu	Arg	Arg	Lys	Gln	Leu	Arg	Asp	Gln	
				245					250					255		
Tyr	Cys	Phe	Glu	Cys	Asp	Cys	Phe	Arg	Cys	Gln	Thr	Gln	Asp	Lys	Asp	
			260					265					270			
Ala	Asp	Met	Leu	Thr	Gly	Asp	Glu	Gln	Val	Trp	Lys	Glu	Val	Gln	Glu	
		275					280					285				
Ser	Leu	Lys	Lys	Ile	Glu	Glu	Leu	Lys	Ala	His	Trp	Lys	Trp	Glu	Gln	
	290				295						300					
Val	Leu	Ala	Met	Cys	Gln	Ala	Ile	Ile	Ser	Ser	Asn	Ser	Glu	Arg	Leu	
305					310				315						320	
Pro	Asp	Ile	Asn	Ile	Tyr	Gln	Leu	Lys	Val	Leu	Asp	Cys	Ala	Met	Asp	
			325					330						335		
Ala	Cys	Ile	Asn	Leu	Gly	Leu	Leu	Glu	Glu	Ala	Leu	Phe	Tyr	Gly	Thr	
			340					345					350			
Arg	Thr	Met	Glu	Pro	Tyr	Arg	Ile	Phe	Phe	Pro	Gly	Ser	His	Pro	Val	
		355					360					365				
Arg	Gly	Val	Gln	Val	Met	Lys	Val	Gly	Lys	Leu	Gln	Leu	His	Gln	Gly	
	370					375					380					
Met	Phe	Pro	Gln	Ala	Met	Lys	Asn	Leu	Arg	Leu	Ala	Phe	Asp	Ile	Met	
385					390					395					400	
Arg	Val	Thr	His	Gly	Arg	Glu	His	Ser	Leu	Ile	Glu	Asp	Leu	Ile	Leu	
				405					410					415		
Leu	Leu	Glu	Glu	Cys	Asp	Ala	Asn	Ile	Arg	Ala	Ser					
			420					425								

Exogenous expression of ZNFN3A1 in NIH3T3 cells resulted in increased cell growth. In contrast, suppression of its expression with antisense S-oligonucleotides resulted in a growth-inhibition of hepatoma cells.

##### 5 Methods of inhibiting cell growth

The present invention relates to inhibiting cell growth, *i.e.*, cancer cell growth by inhibiting ZNFN3A1 expression. ZNFN3A1 expression is inhibited by small interfering RNA (siRNA) that specifically target of the ZNFN3A1 gene. A ZNFN3A1 target includes, for example, nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1.

In non-mammalian cells, double-stranded RNA (dsRNA) has been shown to exert a strong and specific silencing effect on gene expression, which is referred as RNA interference (RNAi) (3). dsRNA is processed into 20-23 nucleotides dsRNA called small



- 8 -

interfering RNA (siRNA) by an enzyme containing RNase III motif. The siRNA specifically targets complementary mRNA with a multicomponent nuclease complex (4, 5). In mammalian cells, siRNA composed of 20 or 21-mer dsRNA with 19 complementary nucleotides and 3' terminal noncomplementary dimmers of thymidine or uridine, have  
5 been shown to have a gene specific knock-down effect without inducing global changes in gene expression (6). In addition, plasmids containing small nuclear RNA (snRNA) U6 or polymerase III H1-RNA promoter effectively produce such short RNA recruiting type III class of RNA polymerase III and thus can constitutively suppress its target mRNA (7, 8).

13 different expression plasmids were constructed to express hairpin-looped  
10 ZNFN3A1-siRNA (See Example 2). The plasmids were tested for their ability to inhibit cell growth. Four plasmids (psiU6BX-ZNFN3A1-4, -8, -12 and -13) markedly and five plasmids (psiU6BX-ZNFN3A1-2, -5, -6, -7, and -10) moderately suppressed endogenous ZNFN3A1 expression, while the remaining four plasmids (psiU6BX-ZNFN3A1-1, -3, -9 and -11 exhibited no or little effect on the expression. (Figure 1). Various human  
15 hepatoma and colorectal cancer cells transfected with psiU6BX-siZNFN3A1-12, showed reduced number of surviving cells compared to control plasmids. FACS analysis revealed that their death was due to apoptosis.

The growth of cells are inhibited by contacting a cell, with a composition containing a ZNFN3A1 siRNA. The cell is further contacted with a transfection agent.  
20 Suitable transfection agents are known in the art. By inhibition of cell growth is meant the cell proliferates at a lower rate or has decreased viability compared to a cell not exposed to the composition. Cell growth is measured by methods known in the art such as, the MTT cell proliferation assay.

The ZNFN3A1-siRNA is directed to a single target ZNFN3A1 gene sequence.  
25 Alternatively, the siRNA is directed to multiple target ZNFN3A1 gene sequences. For example, the composition contains ZNFN3A1- siRNA directed to two, three, four, or five or more ZNFN3A1 target sequences. By ZNFN3A1 target sequence is meant a nucleotide sequence that is identical to a portion of the ZNFN3A1 gene. The target sequence can include the 5' untranslated (UT) region, the open reading frame (ORF) or the 3'  
30 untranslated region of the human ZNFN3A1 gene. Alternatively, the siRNA is a nucleic acid sequence complementary to an upstream or downstream modulator of ZNFN3A1 gene expression. Examples of upstream and downstream modulators include, a transcription

- 9 -

factor that binds the ZNFN3A1 gene promoter, a kinase or phosphatase that interacts with the ZNFN3A1 polypeptide, a ZNFN3A1 promoter or enhancer.

ZNFN3A1- siRNA which hybridize to target mRNA decrease or inhibit production of the ZNFN3A1 polypeptide product encoded by the ZNFN3A1 gene by associating with the normally single-stranded mRNA transcript, thereby interfering with translation and thus, expression of the protein. The siRNA is less than 500, 200, 100, 50, or 25 nucleotides in length. Preferably the siRNA is 19-25 nucleotides in length. Exemplary nucleic acid sequence for the production of ZNFN3A1-siRNA include the sequences of nucleotides 451-471 (SEQ ID NO:58), 532-552 (SEQ ID NO:60), 623-643 (SEQ ID NO:61), 625-645 (SEQ ID NO:62), 636-656 (SEQ ID NO:63), 726-746 (SEQ ID NO:64), 923-943 (SEQ ID NO:66), 1065-1085 (SEQ ID NO:68), or 1258-1278 (SEQ ID NO:69) of SEQ ID NO:1 as the target sequence. Furthermore, in order to enhance the inhibition activity of the siRNA, nucleotide "u" can be added to 3' end of the antisense strand of the target sequence. The number of "u"s to be added is at least 2, generally 2 to 10, preferably 2 to 5. The added "u"s form single strand at the 3' end of the antisense strand of the siRNA.

The cell is any cell that expresses or over-expresses ZNFN3A1. The cell is a hepatic cell or an epithelial cell such as a colon cell. Alternatively, the cell is a tumor cell such as a carcinoma, adenocarcinoma, blastoma, leukemia, myeloma, or sarcoma. The cell is a hepatocellular carcinoma or a colorectal adenocarcinoma cell.

An ZNFN3A1-siRNA is directly introduced into the cells in a form that is capable of binding to the mRNA transcripts. Alternatively, the DNA encoding the ZNFN3A1-siRNA is in a vector.

Vectors are produced for example by cloning a ZNFN3A1 target sequence into an expression vector operatively-linked regulatory sequences flanking the ZNFN3A1 sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands (Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.-J., Ehsani, A., Salvaterra, P., and Rossi, J. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnology 20 : 500-505.). An RNA molecule that is antisense to ZNFN3A1 mRNA is transcribed by a first promoter (e.g., a promoter sequence 3' of the cloned DNA) and an RNA molecule that is the sense strand for the ZNFN3A1 mRNA is transcribed by a second promoter (e.g., a promoter sequence 5' of the cloned DNA). The sense and antisense strands hybridize *in vivo* to generate siRNA constructs for

- 10 -

silencing of the ZNFN3A1 gene. Alternatively, two constructs are utilized to create the sense and anti-sense strands of a siRNA construct. Cloned ZNFN3A1 can encode a construct having secondary structure, e.g., hairpins, wherein a single transcript has both the sense and complementary antisense sequences from the target gene.

5 A loop sequence consisting of an arbitrary nucleotide sequence can be located between the sense and antisense sequence in order to form the hairpin loop structure. Thus, the present invention also provides siRNA having the general formula 5'-[A]-[B]-[A']-3', wherein [A] is a ribonucleotide sequence corresponding to a sequence selected from the group consisting of nucleotides 451-471 (SEQ ID NO:58), 532-552 (SEQ ID NO:60), 623-643  
10 (SEQ ID NO:61), 625-645 (SEQ ID NO:62), 636-656 (SEQ ID NO:63), 726-746 (SEQ ID NO:64), 923-943 (SEQ ID NO:66), 1065-1085 (SEQ ID NO:68), and 1258-1278 (SEQ ID NO:69) of SEQ ID NO:1,

[B] is a ribonucleotide sequence consisting of 3 to 23 nucleotides, and

[A'] is a ribonucleotide sequence consisting of the complementary sequence of [A]

15 The region [A] hybridizes to [A'], and then a loop consisting of region [B] is formed. The loop sequence may be preferably 3 to 23 nucleotide in length. The loop sequence, for example, can be selected from group consisting of following sequences ([http://www.ambion.com/techlib/tb/tb\\_506.html](http://www.ambion.com/techlib/tb/tb_506.html)). Furthermore, loop sequence consisting of 23 nucleotides also provides active siRNA (Jacque, J.-M., Triques, K., and Stevenson,  
20 M. (2002) Modulation of HIV-1 replication by RNA interference. Nature 418 : 435-438.).

AUG :Sui, G., Soohoo, C., Affar, E.B., Gay, F., Shi, Y., Forrester, W.C., and Shi, Y. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. US A 99(8): 5515-5520.

CCC, CCACC or CCACACC: Paul, C.P., Good, P.D., Winer, I., and Engelke, D.R.  
25 (2002) Effective expression of small interfering RNA in human cells. Nature Biotechnology 20 : 505-508.

UUCG: Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.-J., Ehsani, A., Salvaterra, P., and Rossi, J. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnology 20 : 500-505.

30 CTCGAG or AAGCUU: Editors of Nature Cell Biology (2003) Whither RNAi? Nat Cell Biol. 5:489-490.

- 11 -

UUCAAGAGA: Yu, J.-Y., DeRuiter, S.L., and Turner, D.L. (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc. Natl. Acad. Sci. USA* 99(9) : 6047-6052.

For example, preferable siRNAs having hairpin loop structure of the present invention are shown below. In the following structure, the loop sequence can be selected from group consisting of AUG, CCC, UUCG, CCACC, CTCGAG, AAGCUU, CCACACC, and UUCAAGAGA. Preferable loop sequence is UUCAAGAGA ("ttcaagaga" in DNA).

aaucagagaagcuuuacucau-[B]-augaguaaagcuucucugauu (for target sequence of SEQ ID

10 NO:58)

aacucguaaugacauuucac-[B]-guugaaaugucanuacgaguu (for target sequence of SEQ ID NO:60)

aaaagugaucugcaacucuuu-[B]-aaagaguugcagaucauuuu (for target sequence of SEQ ID NO:61)

15 aagugaucugcaacucuuuca-[B]-ugaaagaguugcagaucauu (for target sequence of SEQ ID NO:62)

aacucuuucaccaucuguaau-[B]-auuacagauggugaaagaguu (for target sequence of SEQ ID NO:63)

20 aacuguucgauuguguucaau-[B]-auugaacacaucgaacaguu (for target sequence of SEQ ID NO:64)

aacuggugaugagcaaguaug-[B]-cauacuugcucauccaguu (for target sequence of SEQ ID NO:66)

aacauuaccagcugaaggug-[B]-caccuucagcugguagauguu (for target sequence of SEQ ID NO:68)

25 aagcaugaagaauucugagac-[B]-gucucagaauucuauugcuu (for target sequence of SEQ ID NO:69)

The regulatory sequences flanking the ZNFN3A1 sequence are identical or are different, such that their expression can be modulated independently, or in a temporal or spatial manner. siRNAs are transcribed intracellularly by cloning the ZNFN3A1 gene templates into a vector containing, *e.g.*, a RNA pol III transcription unit from the small nuclear RNA (snRNA) U6 or the human H1 RNA promoter. For introducing the vector into the cell, transfection-enhancing agent can be used. FuGENE (Rochediagnostics),

30



- 12 -

Lipofectamin 2000 (Invitrogen), Oligofectamin (Invitrogen), and Nucleofactor (Wako pure Chemical) are useful as the transfection-enhancing agent.

Oligonucleotides and oligonucleotides complementary to various portions of ZNFN3A1 mRNA were tested *in vitro* for their ability to decrease production of ZNFN3A1 in tumor cells (e.g., using the Alexander and HepG2 hepatocellular carcinoma (HCC) cell line and the HCT116 and SW948 colorectal cancer cell line) according to standard methods. A reduction in ZNFN3A1 gene product in cells contacted with the candidate siRNA composition compared to cells cultured in the absence of the candidate composition is detected using ZNFN3A1-specific antibodies or other detection strategies.

Sequences which decrease production of ZNFN3A1 in *in vitro* cell-based or cell-free assays are then tested for their inhibitory effects on cell growth. Sequences which inhibit cell growth in *in vitro* cell-based assay are tested *in vivo* in rats or mice to confirm decreased ZNFN3A1 production and decreased tumor cell growth in animals with malignant neoplasms.

#### 15 Methods of treating malignant tumors

Patients with tumors characterized as over-expressing ZNFN3A1 are treated by administering ZNFN3A1-siRNA. siRNA therapy is used to inhibit expression of ZNFN3A1 in patients suffering from or at risk of developing, for example, hepatocellular carcinomas, or colorectal cancer. Such patients are identified by standard methods of the particular tumor type. Hepatocellular carcinoma is diagnosed for example, by enlargement of the liver, tomography, ultrasound or biopsy. Colorectal cancer is diagnosed for example, by blood in stool, colonoscopy, flexible sigmoidoscopy, CEA Assay, double contrast barium enema CT Scan, tomography or biopsy.

Treatment is efficacious if the treatment leads to clinical benefit such as, a reduction in expression of ZNFN3A1, or a decrease in size, prevalence, or metastatic potential of the tumor in the subject. When treatment is applied prophylactically, "efficacious" means that the treatment retards or prevents tumors from forming or prevents or alleviates a symptom of clinical symptom of the tumor. Efficaciousness is determined in association with any known method for diagnosing or treating the particular tumor type.

siRNA therapy is carried out by administering to a patient a siRNA by standard vectors and/or gene delivery systems. Suitable gene delivery systems may include liposomes, receptor-mediated delivery systems, or viral vectors such as herpes viruses,



- 13 -

retroviruses, adenoviruses and adeno-associated viruses, among others. A reduction in ZNFN3A1 production results in a decrease ZNFN3A1 complex formation with KIAA0054 protein and RNA polymerase II or a decrease in ZNFN3A1 protein expression. A therapeutic nucleic acid composition is formulated in a pharmaceutically acceptable carrier.

5 The therapeutic composition may also include a gene delivery system as described above. Pharmaceutically acceptable carriers are biologically compatible vehicles which are suitable for administration to an animal, *e.g.*, physiological saline. A therapeutically effective amount of a compound is an amount which is capable of producing a medically desirable result such as reduced production of a ZNFN3A1 gene product, reduction of cell  
10 growth, *e.g.*, proliferation, or a reduction in tumor growth in a treated animal.

Parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal delivery routes, may be used to deliver ZNFN3A1-siRNA compositions. For treatment of hepatic tumors, direct infusion the portal vein is useful.

Dosages for any one patient depends upon many factors, including the patient's size,  
15 body surface area, age, the particular nucleic acid to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Dosage for intravenous administration of nucleic acids is from approximately  $10^6$  to  $10^{22}$  copies of the polynucleotide.

The polynucleotides are administered by standard methods, such as by injection  
20 into the interstitial space of tissues such as muscles or skin, introduction into the circulation or into body cavities or by inhalation or insufflation. Polynucleotides are injected or otherwise delivered to the animal with a pharmaceutically acceptable liquid carrier, *e.g.*, a liquid carrier, which is aqueous or partly aqueous. The polynucleotides are associated with a liposome (*e.g.*, a cationic or anionic liposome). The polynucleotide  
25 includes genetic information necessary for expression by a target cell, such as a promoters.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable  
30 methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In

- 14 -

case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting

#### Brief Description of the Drawings

5           Fig. 1 is a photograph of an immunoblot showing the effect of ZNFN3A1 siRNAs on exogenous ZNFN3A1 expression in COS7 cells.

          Fig. 2 is a photograph of an immunoblot showing the expression of ZNFN3A1 protein in hepatoma and colon cancer cell lines.

10           Fig. 3 is a photograph of an immunoblot showing the effect of ZNFN3A1-siRNAs on endogenous ZNFN3A1 expression in SNU475 cell transfected with psiU6BX-ZNFN3A1-1, -4, -12 or psiU6BX-mock plasmids.

          Fig. 4A -B are bar charts showing the effect of ZNFN3A1-siRNAs on cell growth in SNU475 cells. Viability of transfected cells was measured by MTT assay 6 (Panel A) and 9 (panel B) days after the transfection.

15           Fig. 5 are bar charts showing growth suppressive effect of ZNFN3A1-siRNAs in various human hepatoma and colon cancer cells. Viability of transfected cells was measured by MTT assay, 9 to 12 days after the transfection.

          Figure 6 is an illustration showing cell death in response to ZNFN3A1-siRNAs in SNU475 cell detected by FACS analysis.

20

#### Best Mode for Carrying out the Invention

          The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

25   [Example 1] General Methods

#### Cell lines and tissue specimens

          Human hepatoma cell lines Alexander and HepG2, human colon cancer lines HCT116 and SW948, and monkey fibroblast cell line COS7 were obtained from the American Type Culture Collection (ATCC). Human hepatoma cell line Huh7 was  
30   obtained from Japanese Collection of Research Bioresources (JCRB). Human hepatoma

- 15 -

cell lines, SNU398, SNU423, SNU449 and SNU475 were obtained from the Korea cell-line bank. All these cells are publicly available.

All cell lines were grown in monolayers in appropriate media: Dulbecco's modified Eagle's medium for Alexander, Huh7, HepG2 and COS7; McCoy's 5A for HCT116; Leibovitz's L-15 for SW948; RPMI1640 for SNU398, SNU423, SNU449 and SNU475 supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution (Sigma). All cells were maintained at 37 °C in humid air with 5% CO<sub>2</sub>, (Alexander, Huh7, HepG2, SNU398, SNU423, SNU449, SNU475, HCT116, and COS7) or without CO<sub>2</sub> (SW948).

#### Cloning of ZNFN3A1

Cloning of *ZNFN3A1* was done by PCR using KOD-plus (TOYOBO). For E. Coli expression, coding region of *ZNFN3A1* was cloned in the *EcoR* I-*Kpn* I site of pET21a. For mammalian cell expression, coding region of *ZNFN3A1* was cloned in the *EcoR* I-*Kpn* I site of pcDNA3.1 (+) and (-) (Invitrogen), *EcoR* I-*Kpn* I site of pFLAG and *EcoR* I-*Kpn* I site of pEGFP (Clontech). Coding region of *KIAA0054* was cloned in the *EcoR* I-*Xho* I site of pCMV-HA (Clontech).

#### ZNFN3A1 Polyclonal Antibody Production

Rabbit anti-ZNFN3A1 polyclonal antibody was generated. Full coding sequence of *ZNFN3A1* was amplified by PCR reaction using testis cDNA as a template and cloned in pET21 a (Novagen). The cloned vector was transfected into BL21-CodonPlus® competent cells (Stratagene). Recombinant ZNFN3A1 protein was induced by 1.0 mM IPTG at 30°C for 6 h. His-ZNFN3A1 fusion protein was purified using Pro Bond™ Resin (Invitrogen). Rabbits were immunized ten times with purified His-ZNFN3A1. Immunoblotting with this polyclonal antibody showed single 50 kD band of FLAG-tagged ZNFN3A1, which was identical pattern to that detected using anti-FLAG monoclonal antibody (Sigma) (data not shown).

#### RNA preparation and RT-PCR

Total RNA was extracted with Trizol reagent (Life technologies) according to the manufacturer's protocol. Ten-microgram aliquots of total RNA were reversely transcribed for single-stranded cDNAs using poly dT<sub>12-18</sub> primer (Amersham Biosciences) with

- 16 -

Superscript II reverse transcriptase (Life Technologies). Each single-stranded cDNA was diluted for subsequent PCR amplification. Standard RT-PCR was carried out in a 20 µl volume of PCR buffer (TAKARA), and amplified for 4 min at 94 °C for denaturing, followed by 20 (for *GAPDH*) or 30 (for *ZNFN3A1*) cycles of 94 °C for 30 s, 56 °C for 30 s, 72 °C for 30 s, in the Gene Amp PCR system 9700 (Perkin-Elmer). Primer sequence were as follows,

for *GAPDH*

forward; 5'-ACAACAGCCTCAAGATCATCAG-3' (SEQ ID No: 29) and  
reverse; 5'-GGTCCACCACTGACACGTTG-3' (SEQ ID No: 30),

10 for or *ZNFN3A1*

forward; 5'-TTCCCGATATCAACATCTACCAG-3' (SEQ ID No: 31) and  
reverse; 5'-AGTGTGTGACCTCAATAAGGCAT-3' (SEQ ID No: 32).

#### Construction of psiU6BX6 Plasmid

15 The DNA fragment encoding siRNA was inserted into the GAP at nucleotide 485-490 as indicated (-) in the following plasmid sequence (SEQ ID No: 33).

```
GACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACCTCTCAGTACAATCTGCTCTGGAT
CCACTAGTAACGGCCGCCAGTGTGCTGGAATTCGGCTTGGGGATCAGCGTTTGAGTAAGA
GCCCCGCTCTGAACCCCTCCGCGCCGCCCGGCCCGAGTGGAAAGACGCGCAGGCAAAACG
CACCACGTGACGGAGCGTGACCGCGCGCCGAGCGCGCGCCAAGGTCGGGCAGGAAGAGGG
CCTATTTCCCATGATTCCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAAT
TAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTA
ATAATTTCTTGGGTAGTTTGCAGTTTTTAAATTTATGTTTTTAAATGGACTATCATATGCT
TACCGTAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAA
CACC-----TTTTTACATCAGGTTGTTTTTCTGTTTGGTTTTTTTTTTTACACCACGTTT
ATACGCCGGTGCACGGTTTACCACCTGAAAACACCTTTCATCTACAGGTGATATCTTTTAA
CACAAATAAAATGTAGTAGTCCTAGGAGACGGAATAGAAGGAGGTGGGGCCTAAAGCCGA
ATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGTGAGGCGGAAAGAACCAGCTGGG
GCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTGTGGTGG
TTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCGCTTTCT
TCCCTTCCTTTCTCGCCACGTTTCGCGCGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCC
CTTTAGGGTTCCGATTTAGTGCTTTACGECACCTCGACCCCAAAAACCTTGATTAGGGTG
ATGGTTCACGTAGTGGGCCATCCCCCTGATAGACGGTTTTTTCGCCCTTTGACGTTGAGT
CCACGTTCTTTAATAGTGGACTCTTGTTCCAAACCTGGAACAACACTCAACCCCTATCTCGG
TCTATTCTTTTGAATTTATAAGGGATTTTGCCGATTTCCGCCCTATTGGTTAAAAAATGACC
TGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGG
AAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGC
```



AACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCT  
CAATTAGTCAGCAACCATAGTCCCCGCCCTAACTCCGCCCATCCCCGCCCTAACTCCGCC  
CAGTTCCGCCCATTTCTCCGCCCATGGCTGACTAATTTTTTTTATTATGCAGAGGCCGA  
GGCCGCCCTCTGCTCTGAGCTATTCCAGAAGTACTGAGGAGCCTTTTTTGGAGGCCTAGG  
CTTTTGCAAAAAGCTCCCCGGAGCTTGTATATCCATTTTCCGATCTGATCAAGAGACAGG  
ATGAGGATCGTTTCCGATGATTGAACAAGATGGATTCACGCAGGTTCTCCGCCGCCCTTG  
GGTGGAGAGGCTATTCCGCTATGACTGGGCACAAACAGACAATCCGCTGCTCTGATGCCGC  
CGTGTTCGCCCTGTCAAGCGCAGGGGCCGCCGGTTCTTTTTTGTCAAGACCGACCTGTCCGG  
TGCCCTGAATGAAGTGCAGGACGAGGCGAGCGGCTATCGTGGCTGCGCCAGCAGGGCGT  
TCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGG  
CGAAGTCCCGGGGCAGGATCTCCTGTCACTCACCTTGCTCCTGCGGAGAAAGTATCCAT  
CATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCA  
CCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCA  
GGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAAGTGTTCGCCAGGCTCAA  
GGCGCGCATGCCCCAGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAA  
TATCATGGTGGAAAATGGCCGCTTTTCTGGATTTCATCGACTGTGGCCGGCTGGGTGTGGC  
GGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGA  
ATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTTCGAGCGCATCGC  
CTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTGAAATGACCGAC  
CAAGCGACGCCCAACCTGCCATCACGAGATTTGATTCCACCGCCGCTTCTATGAAAGG  
TTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTC  
ATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAA  
AGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTTCACTGCATTCTAGTTGTGGT  
TTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGC  
TTGGCGTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAAATCCA  
CACACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCATAATGAGTGAGCTAA  
CTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCAGTCGGGAAACCTGTCTGTGCCAG  
CTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCC  
GCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTGCTCGGCTGCGGCGAGCGGTATCAGCT  
CACTCAAAGGCGGTAAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG  
TGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTC  
CATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGA  
AACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCT  
CCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCCCTTCTCCCTTCGGGAAGCGTG  
GCGCTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCCGTTGAGGTCTTCCCTCCAAG  
CTGGGCTGTGTGCAGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACATAT  
CGTCTTGAGTCCAACCCCGTAAGACACGACTTATCGCCACTGCGACGACCACTCGGTAAC  
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAAC  
TACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTC



- 18 -

```
GGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTTTTTTT
GTTTGCAAGCAGCAGATTACCGCCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTT
TCTACGGGGTCTGACGCTCAGTEGAACGAAACTCACGTTAAGGGATTTTGGTCATGAGA
TTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTAAATCAATC
TAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCT
ATCTCAGCGATCTGTCTATTTTCTTCATCCATAGTTGCTGACTCCCCGTCGTGTAGATA
ACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTCTGCAATGATACCGCGAGACCCA
CGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGA
AGTGGTCTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGA
GTAAAGTAGTTCCGCGAGTTAATAGTTTGGCGCAACGTTGTTGCCATTGCTACAGGCATCGTG
GTGTCACGCTCGTCGTTTGGTATGGCTTCATTGAGCTCCGCTTCCCAACGATCAAGGCGA
GTTACATGATCCCCCATGTTGTGCAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTT
GTCAGAAAGTAAGTTGGCCGCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCT
CTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCA
TTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAAT
ACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGA
AAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCC
AACTGATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGG
CAAAATGCCGCAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTC
CTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTT
GAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGGCACATTTCCCCGAAAAGTGCCA
CCTGACGTC
```

snRNA U6 gene is reported to be transcribed by RNA polymerase III, which produce short transcripts with uridines at the 3' end. The genomic fragment of the snRNA U6 gene containing the promoter region was amplified by PCR using a set of primers,

5'-GGGGATCAGCGTTTGAGTAA-3' (SEQ ID No: 34), and

5'-TAGGCCCCACCTCCTTCTAT-3' (SEQ ID No: 35) and human placental DNA as a template. The product was purified and cloned into pCR plasmid vector using a TA cloning kit according to the supplier's protocol (Invitrogen). The *Bam*HI, *Xho*I fragment containing the snRNA U6 gene was purified and cloned into nucleotide 1257 to 56 fragment of pcDNA3.1(+) plasmid, which was amplified by PCR with a set of primer, 5'-TGCGGATCCAGAGCAGATTGTACTGAGAGT-3' (SEQ ID No: 36) and 5'-CTCTATCTCGAGTGAGGCGGAAAGAACCA-3' (SEQ ID No: 37). The ligated DNA was used for a template of PCR with primers,

- 19 -

5'-TTTAAGCTTGAAGACTATTTTACATCAGGTTGTTTTTCT-3' (SEQ ID No: 38)  
and

5'-TTTAAGCTTGAAGACACGGTGTTCGTCCTTTCCACA-3' (SEQ ID No: 39). The  
product was digested with HindIII, which was subsequently self-ligated to produce  
5 psiU6BX vector plasmid. For the control, psiU6BX-EGFP was prepared by cloning  
double-stranded oligonucleotides of

5'-CACCGAAGCAGCACGACTTCTTCTTCAAGAGAGAAGAAGTCGTGCT  
GCTTC-3' (SEQ ID No: 40) and

5'-AAAAGAAGCAGCACGACTTCTTCTTCTTGAAGAAGAAGTCGTGCT  
10 GCTTC-3' (SEQ ID No: 41) into the BbsI site in the psiU6BX vector.

#### Immunoblotting

The polyclonal antibody to ZNFN3A1 was previously purified from sera of  
immunized rabbits with recombinant His-tagged ZNFN3A1 protein. Proteins were  
15 separated by 10% SDS-PAGE and immunoblotted with the anti-ZNFN3A1 antibody.  
HRP-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) served  
as the secondary antibody for the ECL Detection System (Amersham Pharmacia Biotech,  
Piscataway, NJ). Immunoblotting with the anti-ZNFN3A1 antibody showed single 50 kD  
band of FLAG-tagged ZNFN3A1, which was identical pattern to that detected using anti-  
20 FLAG antibody

#### 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

Cells were transfected with psiU6BX-siZNFN3A1 or control plasmids and  
maintained in the culture media supplemented with optimum concentration of geneticin.  
25 Six to twelve days after transfection, the medium was replaced with fresh medium  
containing 500 µg/ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium  
bromide) (Sigma) and the plates were incubated for four hours at 37°C. Subsequently, the  
cells were lysed by the addition of 1 ml of 0.01 N HCl/10%SDS and. absorbance of lysates  
was measured with an ELISA plate reader at a test wavelength of 570 nm (reference, 630  
30 nm). The cell viability was represented by the absorbance compared to that of control cells.

#### Flow cytometry

The effect of ZNFN3A1 in cell cycle progression was determined by flow

- 20 -

cytometry. Cells were plated at a density of  $1 \times 10^5$  cells/100 mm dish. The cells were trypsinized at the given time course, collected in PBS and fixed in 70% cold ethanol. After RNase treatment, cells were stained with propidium iodide (50  $\mu$ g/ml) in PBS. Flow cytometry was performed on a Becton Dickinson FACScan and analyzed by CellQuest and  
5 ModFit software (Verity Software House). The percentages of nuclei in G0/G1, S and G2/M phases of the cell cycle, and any sub-G1 population were determined from at least 20,000 ungated cells.

To examine the role of ZNFN3A1-siRNAs in cell cycle,  $1 \times 10^5$  of SNU475 cells transfected with psiU6BX-ZNFN3A1 or control plasmids were collected by trypsinization  
10 at 5 days after transfection. After fixation in 70% cold ethanol, cells were treated with RNase and propidium iodide (50  $\mu$ g/ml) in PBS, and analyzed by a FACScan (Becton Dickinson, San Jose, CA). The percentages of cells in G0/G1, S and G2/M phases of the cell cycle, and any sub-G1 population were determined from at least 20,000 ungated cells using ModFit software (Verity Software House)

15 [Example 2] Production and Characterization of Plasmids Expressing ZNFN3A1 siRNAs

The entire coding sequence of *ZNFN3A1* was amplified with a set of primers, 5'-GGGGTACCAGGATGGAGCCGCTGAAGGTGG-3' (SEQ ID No: 42), and 5'-GGGAATTCTTAGGATGCTCTGATGTTGGCGTCG-3' (SEQ ID No: 43) and cloned  
20 into the appropriate cloning sites of pcDNA 3.1(+) vector (Invitrogen) (pcDNA-ZNFN3A1). Plasmids expressing ZNFN3A1-siRNAs were prepared by cloning of double-stranded oligonucleotides into psiU6BX vector.

The nucleotide sequence of the siRNAs were designed using an siRNA design computer program available from the Ambion website.

25 ([http://www.ambion.com/techlib/misc/siRNA\\_finder.html](http://www.ambion.com/techlib/misc/siRNA_finder.html)). Briefly, nucleotide sequences for siRNA synthesis are selected using the following protocol.

*Selection of siRNA Target Sites:*

1. Starting with the AUG start codon of the *ZNFN3A1* transcript, scan downstream for an AA dinucleotide sequences. The occurrence of  
30 each AA and the 3' adjacent 19 nucleotides are recorded as potential siRNA target sites. Tuschl et al. recommend against designing siRNA to the 5' and 3' untranslated regions (UTRs) and regions near the start codon (within 75bases) as these may be richer in regulatory protein binding sites.

- 21 -

UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex.

2. The potential target sites are compared to the appropriate genome database (human, mouse, rat, etc.) to eliminate target sequences with significant homology to other coding sequences.

3. Qualifying target sequences are selected for synthesis. Several target sequences along the length of the gene are selected for evaluation.

The oligonucleotides used for ZNFN3A1 siRNAs are shown below. psiU6BX-ZNFN3A1 1-13 (siRNA 1-13) were prepared by cloning the following double-stranded

oligonucleotide into the BbsI site of the psiU6 vector. The corresponding nucleotide position relative to the ZNFN3A1 nucleic acid sequence of SEQ ID NO:1 is listed for each oligonucleotide sequence. Each oligonucleotide is a combination of a sense nucleotide sequence and an antisense nucleotide sequence of the target sequence ZNFN3A1. The nucleotide sequences of the hairpin loop structure and target sequence of siRNA1 to 13 are shown in SEQ ID NO:44 to SEQ ID NO:56 and SEQ ID NO:57 to SEQ ID NO:69, respectively (endonuclease recognition sites are eliminated from each hairpin loop structure sequence).

psiU6BX-ZNFN3A1-1 /siRNA1: (nucleotide numbers 426-446 of SEQ ID No: 1)

5'- CACCAAACCTTATGGATGGAGCACCTTTCAAGAGAAGGTGCTCCATCCATAA GTTT-3' (SEQ ID NO: 3) and

5'- AAAAAAACCTTATGGATGGAGCACCTTCTCTTGAAAGGTGCTCCATCCATAA GTTT-3' (SEQ ID NO: 4)

psiU6BX-ZNFN3A1-2 /siRNA2: (nucleotide numbers 451-471 of SEQ ID No: 1)

5'-CACCAATCAGAGAAGCTTTACTCATTTCAGAGAATGAGTAAAGCTTCTCTG ATT-3' (SEQ ID NO: 5) and

5'-AAAAAATCAGAGAAGCTTTACTCATTCTCTTGAAATGAGTAAAGCTTCTCTG ATT-3' (SEQ ID NO: 6)

psiU6BX-ZNFN3A1-3 /siRNA3 : (nucleotide numbers 495-515 of SEQ ID No: 1)

- 22 -

siRNA2; 5'- CACCAACAAACTGACTGAAGATAAGTTCAAGAGACTTATCTTCAG  
TCAGTTTGTT-3' (SEQ ID NO: 7) and  
5'-AAAAAACAAACTGACTGAAGATAAGTCTCTTGAAGTTATCTTCAGTCAGTTT  
GTT-3' (SEQ ID NO: 8)

5

psiU6BX-ZNFN3A1-4 /siRNA4: (nucleotide numbers 532-552 of SEQ ID No: 1)  
5'- CACCAACTCGTAATGACATTTCAACTTCAAGAGAGTTGAAATGTCATTACG  
AGTT-3' (SEQ ID NO: 9)and  
5'-AAAAAACTCGTAATGACATTTCAACTCTCTTGAAGTTGAAATGTCATTACGA  
10 GTT-3' (SEQ ID NO: 10)

psiU6BX-ZNFN3A1-5 /siRNA5: (nucleotide numbers 623-643 of SEQ ID No: 1)  
5'- CACCAAAAGTGATCTGCAACTCTTTTTCAAGAGAAAAGAGTTGCAGATCAC  
TTTT-3' (SEQ ID NO: 11)and  
15 5'-AAAAAAAAGTGATCTGCAACTCTTTTCTCTTGAAAAAGAGTTGCAGATCACT  
TTT-3' (SEQ ID NO: 12)

psiU6BX-ZNFN3A1-6 /siRNA6: (nucleotide numbers 625-645 of SEQ ID No: 1)  
5'- CACCAAGTGATCTGCAACTCTTTCATTCAAGAGATGAAAGAGTTGCAGATC  
20 ACTT-3' (SEQ ID NO: 13)and  
5'-AAAAAAGTGATCTGCAACTCTTTCATCTCTTGAATGAAAGAGTTGCAGATCA  
CTT-3' (SEQ ID NO: 14)

psiU6BX-ZNFN3A1-7 /siRNA7: (nucleotide numbers 636-656 of SEQ ID No: 1)  
25 5'- CACCAACTCTTTCACCATCTGTAATTTCAAGAGAATTACAGATGGTGAAAG  
AGTT-3' (SEQ ID NO: 15)and  
5'-AAAAAACTCTTTCACCATCTGTAATTCTCTTGAAATTACAGATGGTGAAAGA  
GTT-3' (SEQ ID NO: 16)

30 psiU6BX-ZNFN3A1-8 /siRNA8: (nucleotide numbers 726-746 of SEQ ID No: 1)  
5'-CACCAACTGTTCGATTGTGTTCAATTTCAAGAGAATTGAACACAATCGAACA  
GTT-3' (SEQ ID NO: 17)and



- 23 -

5'-AAAAAACTGTTTCGATTGTGTTCAATTCTCTTGAAATTGAACACAATCGAACA  
GTT-3' (SEQ ID NO: 18)

psiU6BX-ZNFN3A1-9 /siRNA9: (nucleotide numbers 906-926 of SEQ ID No: 1)

5 5'-CACCAAGGATGCTGATATGCTAACTTTCAAGAGAAGTTAGCATATCAGCAT  
CCTT-3' (SEQ ID NO: 19)and

5'-AAAAAAGGATGCTGATATGCTAACTTCTCTTGAAAGTTAGCATATCAGCATC  
CTT-3' (SEQ ID NO: 20)

10 psiU6BX-ZNFN3A1-10 /siRNA10: (nucleotide numbers 923-943 of SEQ ID No: 1)

5'-CACCAACTGGTGATGAGCAAGTATGTTCAAGAGACATACTTGCTCATCACC  
AGTT-3' (SEQ ID NO: 21) and

5'-AAAAAACTGGTGATGAGCAAGTATGTCTCTTGAACATACTTGCTCATCACCA  
GTT-3' (SEQ ID NO: 22)

15

psiU6BX-ZNFN3A1-11 /siRNA11: (nucleotide numbers 937-957 of SEQ ID No: 1)

5'-CACCAAGTATGGAAGGAAGTTCAAGTTCAAGAGACTTGAACCTCCTTCCAT  
ACTT-3' (SEQ ID NO: 23)and

5'-AAAAAAGTATGGAAGGAAGTTCAAGTCTCTTGAACCTTGAACCTCCTTCCATA  
20 CTT-3' (SEQ ID NO: 24)

psiU6BX-ZNFN3A1-12 /siRNA12: (nucleotide numbers 1065-1085 of SEQ ID No: 1)

5'-CACCAACATCTACCAGCTGAAGGTGTTCAAGAGACACCTTCAGCTGGTAGA  
TGTT-3' (SEQ ID NO: 25)and

25 5'-AAAAAACATCTACCAGCTGAAGGTGTCTCTTGAACACCTTCAGCTGGTAGAT  
GTT-3' (SEQ ID NO: 26)

psiU6BX-ZNFN3A1-13 /siRNA13: (nucleotide numbers 1258-1278 of SEQ ID No: 1)

5'-CACCAAGCAATGAAGAATCTGAGACTTCAAGAGAGTCTCAGATTCTTCATT  
30 GCTT-3' (SEQ ID NO: 27) and

5'-AAAAAAGCAATGAAGAATCTGAGACTCTCTTGAAGTCTCAGATTCTTCATTG  
CTT-3' (SEQ ID NO: 28)

- 24 -

psiU6BX-siZNFN3A1 or psiU6BX-mock plasmids were transfected with pcDNA-ZNFN3A1 into COS7 cells using FuGENE6 reagent according to the supplier's recommendations (Roche). The plasmids were solely transfected into SNU479 cells  
5 expressing abundant amount of endogenous ZNFN3A1. Whole extracts of the cells were lysed 2 days after the transfection and utilized for immunoblot analysis.

Among the 13 different expression plasmids expressing ZNFN3A1 siRNAs, psiU6BX-ZNFN3A1-8, -12, and -13 most significantly reduced expression of exogenous ZNFN3A1 by western blot analysis, when they were transfected into COS7 cells together  
10 with pcDNA-ZNFN3A1. Among other plasmids, psiU6BX-ZNFN3A1-4 showed marked reduction, and psiU6BX-ZNFN3A1-2, -5, -6, -7 and -10 exerted moderate suppression, whereas psiU6BX-ZNFN3A1-1, -3, -9 and -11 had no or little effect on the expression (Figure 1). To further examine RNAi activity of ZNFN3A1 siRNAs, we transfected  
psiU6BX-ZNFN3A1-1, -4, -12, or psiU6BX-mock into SNU475 cells that express  
15 abundant amount of ZNFN3A1 (Figure 2). Western blot analysis using the extracts of transfected cells demonstrated marked reduction of endogenous ZNFN3A1 by psiU6BX-ZNFN3A1-12, and moderate suppression by psiU6BX-ZNFN3A1-4 compared to cells transfected with psiU6BX-mock. On the other hand transfection with psiU6BX-ZNFN3A1-1 did not affect expression of ZNFN3A1 (Figure 3).

20 [Example 3] Growth suppression of hepatoma and colon cancer cells by *ZNFN3A1* siRNA

To test whether suppression of *ZNFN3A1* may result in growth suppression of hepatoma cells, SNU475 cells were transfected with either psiU6BX-ZNFN3A1-12, the vector that demonstrated the most knock down effect on the expression; psiU6BX-ZNFN3A1-4 which demonstrated mild silencing effect; psiU6BX-ZNFN3A1-1 which  
25 demonstrated no silencing effect, or psiU6BX-mock. MTT assays at both 6 days and 9 days of transfection showed that psiU6BX-ZNFN3A1-12 has the highest growth inhibitory effect and that psiU6BX-ZNFN3A1-1 did not change the number of surviving cells compared with cells transfected with psiU6BX-mock (Figure 4). The growth inhibitory  
30 effect of the plasmids was correlated to their gene silencing activity. To further demonstrate the growth inhibitory effect of ZNFN3A1-siRNAs, psiU6BX-ZNFN3A1-12;

- 25 -

psiU6BX-EGFP For the control, psiU6BX-EGFP was prepared by cloning the following double-stranded oligonucleotide

5'- CACCGAAGCAGCACGACTTCTTCTTCAAGAGAGAAGAAGTCGTGCT  
GCTTC-3' (SEQ ID No: 40) and

5'- AAAAGAAGCAGCACGACTTCTTCTTCTTGAAGAAGAAGTCGTGCT  
GCTTC-3' (SEQ ID No: 41) into the BbsI site of the psiU6BX vector.

or psiU6BX-mock was transfected into various hepatoma cell lines including SNU398, SNU423, SNU449, Huh7, Alexander, and HepG2 and two colon cancer cell lines, SW948 and HCT116. Transfection of psiU6BX-ZNFN3A1-12 significantly reduced number of surviving cells compared with that of psiU6BX-EGFP or psiU6BX-mock (Figure 5). Furthermore, FACS analysis demonstrated that transfection of psiU6BX-ZNFN3A1-12 increased the number of cells in sub-G1 phase (Figure 6). These results indicate that ZNFN3A1 contributes to aberrant cell growth and/or survival in a wide range of human cancer cells.

#### Industrial Applicability

The present inventors have shown that the cell growth is suppressed by small interfering RNA (siRNA) that specifically target the ZNFN3A1 gene. Thus, this novel siRNAs are useful target for the development of anti-cancer pharmaceuticals. For example, agents that block the expression of ZNFN3A1 or prevent its activity may find therapeutic utility as anti-cancer agents, particularly anti-cancer agents for the treatment of liver cancer or colon cancer, such as HCC or colorectal adenocarcinoma.

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope of the invention.

#### References

- (1) Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringe B, Meyers WC. Hepatocellular carcinoma. Br J Surg. 1998 Oct;85(10):1319-31.
- (2) Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y. Genome-wide analysis of gene expression in human

- 26 -

hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. *Cancer Res.* 2001 Mar 1;61(5):2129-37.

(3) Sharp PA. RNAi and double-strand RNA. *Genes Dev.* 1999 Jan 15;13(2):139-41..

5 (4) Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature.* 2000 Mar 16;404(6775):293-6.

(5) Hannon GJ. RNA interference. *Nature.* 2002 Jul 11;418(6894):244-51.

10 (6) Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature.* 2001 May 24;411(6836):494-8.

(7) Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat Biotechnol.* 2002 May;20(5):497-500

15 (8) Brummelkamp TR, Bernards R, Agami R. A System for Stable Expression of Short Interfering RNAs in Mammalian Cells *Science.* 296(5567):550-553, April 19, 2002.

- 27 -

# CLAIMS

1. A method of inhibiting tumor cell growth in a subject, comprising administering to said subject a composition comprising a ZNFN3A1 small interfering RNA (siRNA).
- 5 2. The method of claim 1, wherein said siRNA comprises a sense ZNFN3A1 nucleic acid and an anti-sense ZNFN3A1 nucleic acid.
3. The method of claim 1, wherein said tumor cell is a colorectal cancer cell or liver cancer cell.
4. The method of claim 3, wherein the colorectal cancer cell is an adenocarcinoma  
10 cell.
5. The method of claim 3, wherein the liver cancer cell is a hepatocellular carcinoma cell.
6. The method of claim 2, said siRNA is specific for a ZNFN3A1 target selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-  
15 656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1.
7. The method of claim 6, said siRNA has the general formula 5'-[A]-[B]-[A']-3', wherein [A] is a ribonucleotide sequence corresponding to a sequence selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-  
20 656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1, [B] is a ribonucleotide sequence consisting of 3 to 23 nucleotides, and [A'] is a ribonucleotide sequence consisting of the complementary sequence of [A].
8. The method of claim 1, wherein said composition comprises a transfection-enhancing agent.
9. An isolated polynucleotide comprising a combination of a sense strand nucleic acid  
25 and an antisense strand nucleic acid, wherein said sense strand nucleic acid comprises nucleotide sequence selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1, and said antisense strand nucleic acid consists of complementary sequence thereof, respectively.



- 28 -

10. The isolated polynucleotide of claim 9, wherein said sense strand nucleic acid and antisense strand nucleic acid are on the same strand.
11. The isolated polynucleotide of claim 9, wherein said sense strand nucleic acid consists of a nucleotide sequence shorter than about 100 nucleotides.
- 5 12. The isolated polynucleotide of claim 11, wherein said sense strand nucleic acid is shorter than about 75 nucleotides.
13. The isolated polynucleotide of claim 12, wherein said sense strand nucleic acid is shorter than about 50 nucleotides.
14. The isolated polynucleotide of claim 13, wherein said sense strand nucleic acid is shorter than about 25 nucleotides.
- 10 15. The isolated polynucleotide of claim 14, wherein said sense strand nucleic acid is between about 19 and about 25 nucleotides in length.
16. A vector comprising a polynucleotide comprising a combination of a sense strand nucleic acid and an antisense strand nucleic acid, wherein said sense strand nucleic acid comprises nucleotide sequence selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1, and said antisense strand nucleic acid consists of complementary sequence thereof, respectively.
- 15 17. The vector of claim 16, wherein said polynucleotide has the general formula 5'-[A]-[B]-[A']-3', wherein [A] is a nucleotide sequence selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1, [B] is a nucleotide sequence consisting of 3 to 23 nucleotides, and [A'] is a nucleotide sequence consisting of the complementary sequence of [A].
- 20 18. A composition comprising at least one siRNA comprising a combination of a sense strand nucleic acid and an antisense strand nucleic acid, wherein said sense strand nucleic acid comprises ribonucleotide sequence corresponding to a sequence selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1, and
- 25

- 29 -

said antisense strand sequence consists of complementary sequence thereof, respectively.

19. A double-stranded molecule comprising a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a ZNFN3A1 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing the ZNFN3A1 gene, inhibits expression of said gene.
20. The double-stranded molecule of claim 19, wherein said ZNFN3A1 target sequence comprises at least about 10 contiguous nucleotides from SEQ ID No:1.
21. The double-stranded molecule of claim 20, wherein said ZNFN3A1 target sequence comprises from about 19 to about 25 contiguous nucleotides from SEQ ID No:1.
22. The double-stranded molecule of claim 21, wherein said ZNFN3A1 target sequence is selected from the group consisting of nucleotides 451-471, 532-552, 623-643, 625-645, 636-656, 726-746, 923-943, 1065-1085, and 1258-1278 of SEQ ID NO:1.
23. The double-stranded molecule of claim 19, wherein a single ribonucleotide transcript comprises the sense strand and the antisense strand, said double-stranded molecule further comprising a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand.
24. The double-stranded molecule of claim 19, wherein the double stranded molecule is an oligonucleotide of less than about 100 nucleotides in length.
25. The double-stranded molecule of claim 24, wherein the double stranded molecule is an oligonucleotide of less than about 75 nucleotides in length.
26. The double-stranded molecule of claim 25, wherein the double stranded molecule is an oligonucleotide of less than about 50 nucleotides in length.

- 30 -

27. The double-stranded molecule of claim 26, wherein the double stranded molecule is an oligonucleotide of less than about 25 nucleotides in length.
28. The double-stranded polynucleotide of claim 27, wherein the double stranded molecule is an oligonucleotide of between about 19 and about 25 nucleotides in length.
29. A vector encoding the double-stranded molecule of claim 19.
30. The vector of claim 29, wherein the vector encodes a transcript having a secondary structure, wherein the transcript comprises the sense strand and the antisense strand.
31. The vector of claim 30, wherein the transcript further comprises a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand.
32. A method to inhibit expression of the ZNFN3A1 gene in a cell of a biological sample, the method comprising introduction of a ribonucleic acid (RNA) into the cell in an amount sufficient to inhibit expression of the ZNFN3A1 gene, wherein the RNA is a double-stranded molecule comprising a sense strand and a antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to a ZNFN3A1 target sequence, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein the sense and the antisense ribonucleotide strands hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing the ZNFN3A1 gene, inhibits expression of said gene.

Figure 1





Figure 2





3/6


**Figure 3**

Figure 4

MTT assay




Figure 5





Figure 6

FACS analysis



Transfected plasmids	Region (%)		
	Sub-G1	G0/G1	S
psiU6 (Mock)	16.01	71.18	5.07
psiU6-EGFP	16.32	58.87	10.91
psiU6-ZNFN#12	62.30	26.23	4.42

G2/M
7.15
12.43
6.53

1/27

## SEQUENCE LISTING

<110> ONCOTHERAPY SCIENCE, INC.  
JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO

<120> COMPOSITIONS AND METHODS OF INHIBITING CELL GROWTH

<130> ONC-A0301P

<150> US 60/450,644

<151> 2003-02-28

<160> 69

<170> PatentIn version 3.1

<210> 1

<211> 1622

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (96)..(1382)

<223>

<400> 1

gtgcgcgcag ggccgcaggcg cgcgggtccc ggcagcccgt gagacgcccg ctgctggacg 60

cgggtagccg tctgaggtgc cggagctgcg ggagg atg gag ccg ctg aag gtg 113  
Met Glu Pro Leu Lys Val  
1 5

gaa aag ttc gca acc gcc aac agg gga aac ggg ctg cgc gcc gtg acc 161  
Glu Lys Phe Ala Thr Ala Asn Arg Gly Asn Gly Leu Arg Ala Val Thr  
10 15 20

ccg ctg cgc ccc gga gag cta ctc ttc cgc tcg gat ccc ttg gcg tac 209  
Pro Leu Arg Pro Gly Glu Leu Leu Phe Arg Ser Asp Pro Leu Ala Tyr  
25 30 35

acg gtg tgc aag ggg agt cgt ggc gtc gtc tgc gac cgc tgc ctt ctc 257  
Thr Val Cys Lys Gly Ser Arg Gly Val Val Cys Asp Arg Cys Leu Leu



2/27

40	45	50	
ggg aag gaa aag ctg atg cga tgc tct cag tgc cgc gtc gcc aaa tac			305
Gly Lys Glu Lys Leu Met Arg Cys Ser Gln Cys Arg Val Ala Lys Tyr			
55	60	65	70
tgt agt gct aag tgt cag aaa aaa gct tgg cca gac cac aag cgg gaa			353
Cys Ser Ala Lys Cys Gln Lys Lys Ala Trp Pro Asp His Lys Arg Glu			
75	80		85
tgc aaa tgc ctt aaa agc tgc aaa ccc aga tat cct cca gac tcc gtt			401
Cys Lys Cys Leu Lys Ser Cys Lys Pro Arg Tyr Pro Pro Asp Ser Val			
90	95		100
cga ctt ctt ggc aga gtt gtc ttc aaa ctt atg gat gga gca cct tca			449
Arg Leu Leu Gly Arg Val Val Phe Lys Leu Met Asp Gly Ala Pro Ser			
105	110		115
gaa tca gag aag ctt tac tca ttt tat gat ctg gag tca aat att aac			497
Glu Ser Glu Lys Leu Tyr Ser Phe Tyr Asp Leu Glu Ser Asn Ile Asn			
120	125		130
aaa ctg act gaa gat aag aaa gag ggc ctc agg caa ctc gta atg aca			545
Lys Leu Thr Glu Asp Lys Lys Glu Gly Leu Arg Gln Leu Val Met Thr			
135	140	145	150
ttt caa cat ttc atg aga gaa gaa ata cag gat gcc tct cag ctg cca			593
Phe Gln His Phe Met Arg Glu Glu Ile Gln Asp Ala Ser Gln Leu Pro			
155	160		165
cct gcc ttt gac ctt ttt gaa gcc ttt gca aaa gtg atc tgc aac tct			641
Pro Ala Phe Asp Leu Phe Glu Ala Phe Ala Lys Val Ile Cys Asn Ser			
170	175		180
ttc acc atc tgt aat gcg gag atg cag gaa gtt ggt gtt ggc cta tat			689
Phe Thr Ile Cys Asn Ala Glu Met Gln Glu Val Gly Val Gly Leu Tyr			
185	190		195
ccc agt atc tct ttg ctc aat cac agc tgt gac ccc aac tgt tcg att			737
Pro Ser Ile Ser Leu Leu Asn His Ser Cys Asp Pro Asn Cys Ser Ile			
200	205		210
gtg ttc aat ggg ccc cac ctc tta ctg cga gca gtc cga gac atc gag			785



4/27

aag aat ctg aga ctg gct ttt gat att atg aga gtg aca cat ggc aga 1313  
 Lys Asn Leu Arg Leu Ala Phe Asp Ile Met Arg Val Thr His Gly Arg  
                   395                  400                  405

gaa cac agc ctg att gaa gat ttg att cta ctt tta gaa gaa tgc gac 1361  
 Glu His Ser Leu Ile Glu Asp Leu Ile Leu Leu Leu Glu Glu Cys Asp  
                   410                  415                  420

gcc aac atc aga gca tcc taa gggaacgcag tcagagggaa atacggcgtg 1412  
 Ala Asn Ile Arg Ala Ser  
                   425

tgtctttgtt gaatgcctta ttgaggtcac acactctatg ctttgtttagc tgtgtgaacc 1472  
 tctcttattg gaaattctgt tccgtgtttg tgtaggtaaa taaaggcaga catggtttgc 1532  
 aaaccacaag aatcattagt tgtagagaag cacgattata ataaattcaa aacatttggt 1592  
 tgaggatgcc aaaaaaaaaa aaaaaaaaaa 1622

<210> 2  
 <211> 428  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Met Glu Pro Leu Lys Val Glu Lys Phe Ala Thr Ala Asn Arg Gly Asn  
 1                  5                  10                  15

Gly Leu Arg Ala Val Thr Pro Leu Arg Pro Gly Glu Leu Leu Phe Arg  
                   20                  25                  30

Ser Asp Pro Leu Ala Tyr Thr Val Cys Lys Gly Ser Arg Gly Val Val  
                   35                  40                  45

Cys Asp Arg Cys Leu Leu Gly Lys Glu Lys Leu Met Arg Cys Ser Gln  
                   50                  55                  60

Cys Arg Val Ala Lys Tyr Cys Ser Ala Lys Cys Gln Lys Lys Ala Trp  
 65                  70                  75                  80

Pro Asp His Lys Arg Glu Cys Lys Cys Leu Lys Ser Cys Lys Pro Arg  
                   85                  90                  95

Tyr Pro Pro Asp Ser Val Arg Leu Leu Gly Arg Val Val Phe Lys Leu

5/27

100	105	110
Met Asp Gly Ala Pro Ser Glu Ser Glu Lys Leu Tyr Ser Phe Tyr Asp		
115	120	125
Leu Glu Ser Asn Ile Asn Lys Leu Thr Glu Asp Lys Lys Glu Gly Leu		
130	135	140
Arg Gln Leu Val Met Thr Phe Gln His Phe Met Arg Glu Glu Ile Gln		
145	150	155
Asp Ala Ser Gln Leu Pro Pro Ala Phe Asp Leu Phe Glu Ala Phe Ala		
165	170	175
Lys Val Ile Cys Asn Ser Phe Thr Ile Cys Asn Ala Glu Met Gln Glu		
180	185	190
Val Gly Val Gly Leu Tyr Pro Ser Ile Ser Leu Leu Asn His Ser Cys		
195	200	205
Asp Pro Asn Cys Ser Ile Val Phe Asn Gly Pro His Leu Leu Leu Arg		
210	215	220
Ala Val Arg Asp Ile Glu Val Gly Glu Glu Leu Thr Ile Cys Tyr Leu		
225	230	235
Asp Met Leu Met Thr Ser Glu Glu Arg Arg Lys Gln Leu Arg Asp Gln		
245	250	255
Tyr Cys Phe Glu Cys Asp Cys Phe Arg Cys Gln Thr Gln Asp Lys Asp		
260	265	270
Ala Asp Met Leu Thr Gly Asp Glu Gln Val Trp Lys Glu Val Gln Glu		
275	280	285
Ser Leu Lys Lys Ile Glu Glu Leu Lys Ala His Trp Lys Trp Glu Gln		
290	295	300
Val Leu Ala Met Cys Gln Ala Ile Ile Ser Ser Asn Ser Glu Arg Leu		
305	310	315
Pro Asp Ile Asn Ile Tyr Gln Leu Lys Val Leu Asp Cys Ala Met Asp		
325	330	335

6/27

Ala Cys Ile Asn Leu Gly Leu Leu Glu Glu Ala Leu Phe Tyr Gly Thr  
 340 345 350

Arg Thr Met Glu Pro Tyr Arg Ile Phe Phe Pro Gly Ser His Pro Val  
 355 360 365

Arg Gly Val Gln Val Met Lys Val Gly Lys Leu Gln Leu His Gln Gly  
 370 375 380

Met Phe Pro Gln Ala Met Lys Asn Leu Arg Leu Ala Phe Asp Ile Met  
 385 390 395 400

Arg Val Thr His Gly Arg Glu His Ser Leu Ile Glu Asp Leu Ile Leu  
 405 410 415

Leu Leu Glu Glu Cys Asp Ala Asn Ile Arg Ala Ser  
 420 425

&lt;210&gt; 3

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 3

caccaaactt atggatggag cacctttcaa gagaaggtgc tccatccata agttt 55

&lt;210&gt; 4

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 4

aaaaaaactt atggatggag cacctttctt tgaaaggtgc tccatccata agttt 55



7/27

<210> 5  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 5  
caccaatcag agaagcttta ctcatttcaa gagaatgagt aaagcttctc tgatt 55

<210> 6  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 6  
aaaaaatcag agaagcttta ctcattctct tgaaatgagt aaagcttctc tgatt 55

<210> 7  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 7  
caccaacaaa ctgactgaag ataagttcaa gagacttate ttcagtcagt ttgtt 55

<210> 8  
<211> 55  
<212> DNA  
<213> Artificial

<220>

8/27

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 8

aaaaaacaaa ctgactgaag ataagtctct tgaacttate ttcagtcagt ttgtt 55

<210> 9

<211> 55

<212> DNA

<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 9

caccaactcg taatgacatt tcaacttcaa gagagttgaa atgtcattac gagtt 55

<210> 10

<211> 55

<212> DNA

<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 10

aaaaaactcg taatgacatt tcaactctct tgaagttgaa atgtcattac gagtt 55

<210> 11

<211> 55

<212> DNA

<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 11

caccaaagt gatctgcaac tctttttcaa gagaaaagag ttgcagatca ctttt 55

<210> 12

9/27

<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 12

aaaaaaaagt gatctgcaac tcttttctct tgaaaaagag ttgcagatca ctttt 55

<210> 13  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 13

caccaagtga tctgcaactc tttcattcaa gagatgaaag agttgcagat cactt 55

<210> 14  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 14

aaaaaagtga tctgcaactc tttcatctct tgaatgaaag agttgcagat cactt 55

<210> 15  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

10/27

&lt;400&gt; 15

caccaactct ttcaccatct gtaatttcaa gagaattaca gatggtgaaa gagtt 55

&lt;210&gt; 16

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 16

aaaaaactct ttcaccatct gtaattctct tgaaattaca gatggtgaaa gagtt 55

&lt;210&gt; 17

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 17

caccaactgt tcgattgtgt tcaatttcaa gagaattgaa cacaatcgaa cagtt 55

&lt;210&gt; 18

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 18

aaaaaactgt tcgattgtgt tcaattctct tgaaattgaa cacaatcgaa cagtt 55

&lt;210&gt; 19

&lt;211&gt; 55

&lt;212&gt; DNA

11/27

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 19

caccaaggat gctgatatgc taactttcaa gagaagttag catatcagca tcctt 55

&lt;210&gt; 20

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 20

aaaaaaggat gctgatatgc taactttctt tgaaagttag catatcagca tcctt 55

&lt;210&gt; 21

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 21

caccaactgg tgatgagcaa gtatgttcaa gagacatact tgctcatcac cagtt 55

&lt;210&gt; 22

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 22

aaaaaactgg tgatgagcaa gtatgttctt tgaacatact tgctcatcac cagtt 55



12/27

<210> 23  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 23

caccaagtat ggaaggaagt tcaagttcaa gagacttgaa cttccttcca tactt 55

<210> 24  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 24

aaaaaagtat ggaaggaagt tcaagtctct tgaacttgaa cttccttcca tactt 55

<210> 25  
<211> 55  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized origonucleotide sequence for siRNA

<400> 25

caccaacatc taccagctga aggtgttcaa gagacacctt cagctggtag atgtt 55

<210> 26  
<211> 55  
<212> DNA  
<213> Artificial

13/27

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 26

aaaaaacatc taccagctga aggtgtctct tgaacacett cagctggtag atgtt 55

&lt;210&gt; 27

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 27

caccaagcaa tgaagaatct gagacttcaa gagagtctca gattcttcat tgctt 55

&lt;210&gt; 28

&lt;211&gt; 55

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized origonucleotide sequence for siRNA

&lt;400&gt; 28

aaaaaagcaa tgaagaatct gagactctct tgaagtctca gattcttcat tgctt 55

&lt;210&gt; 29

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized primer sequence

&lt;400&gt; 29

acaacagcct caagatcatc ag 22

14/27

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized primer sequence

<400> 30  
ggtccaccac tgacacgttg

20

<210> 31  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized primer sequence

<400> 31  
ttcccgatat caacatctac cag

23

<210> 32  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized primer sequence

<400> 32  
agtgtgtgac ctcaataagg cat

23

<210> 33  
<211> 4869  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized plasmid sequence

15/27

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (485)..(490)

&lt;223&gt; "n" indicates GAP.

&lt;400&gt; 33

gacggatcgg	gagatctccc	gatccccctat	ggtgcactct	cagtacaatc	tgctctggat	60
ccactagtaa	cggccgccag	tgtgctggaa	ttcggcttgg	ggatcagcgt	ttgagtaaga	120
gcccgcgtct	gaaccctccg	cgccgccccg	gccccagtg	aaagacgcgc	aggcaaaacg	180
caccacgtga	cggagcgtga	ccgcgcgcgc	agcgcgcgc	aaggctgggc	aggaagaggg	240
cctatttccc	atgattcctt	catatttgca	tatacgatac	aaggctgtta	gagagataat	300
tagaattaat	ttgactgtaa	acacaaagat	attagtlaca	aatacgtgac	gtagaaagta	360
ataatttctt	gggtagtttg	cagtttttaa	attatgtttt	aaaatggact	atcatatgct	420
taccgtaact	tgaaagtatt	tcgatttctt	ggctttatat	atcttgtgga	aaggacgaaa	480
caccnnnnnn	tttttacatc	aggttggttt	tctgtttggt	ttttttttta	caccacgttt	540
atacgccggt	gcacggttta	ccactgaaaa	cacctttcat	ctacaggtga	tatcttttaa	600
cacaaataaa	atgtagtagt	cctaggagac	ggaatagaag	gaggtggggc	ctaaagccga	660
attctgcaga	tatccatcac	actggcggcc	gctcgagtga	ggcggaaaga	accagctggg	720
gctctagggg	gtatccccac	gcgccttgta	gcggcgcatt	aagcgcggcg	ggtgtggtgg	780
ttacgcgcag	cgtgaccgct	acacttgcca	gcgccttagc	gcccgtcctt	ttcgctttct	840
tcccttcctt	tctcgccacg	ttcgccggct	ttccccgtca	agctctaaat	cgggggctcc	900
ctttaggggt	ccgatttagt	gctttacggc	acctcgacct	caaaaaactt	gattaggggt	960
atggttcacg	tagtgggcca	tcgccttgat	agacggtttt	tcgccttttg	acgttgaggt	1020
ccacgttctt	taatagtgga	ctcttggttc	aaactggaac	aacactcaac	cctatctcgg	1080
tctattcttt	tgatttataa	gggattttgc	cgatttcggc	ctattggtta	aaaaatgagc	1140
tgatttaaca	aaaatttaac	gcgaattaat	tctgtggaat	gtgtgtcagt	taggggtgtg	1200
aaagtcccca	ggctccccag	caggcagaag	tatgcaaagc	atgcatctca	attagtcagc	1260
aaccaggtgt	ggaaagtccc	caggctcccc	agcaggcaga	agtatgcaaa	gcatgcatct	1320
caattagtea	gcaaccatag	tcccgcccct	aactccgccc	atcccgcgcc	taactccgcc	1380
cagttccgcc	cattctccgc	cccatggctg	actaattttt	tttatttatg	cagaggccga	1440
ggccgcctct	gcctctgagc	tattccagaa	gtagtgagga	ggcttttttg	gaggcctagg	1500
cttttgcaaa	aagctcccgg	gagcttgat	atccattttc	ggatctgate	aagagacagg	1560
atgaggatcg	tttcgcatga	ttgaacaaga	tggattgcac	gcaggttctc	cggccgcttg	1620
ggtggagagg	ctattcggct	atgactgggc	acaacagaca	atcggctgct	ctgatgccgc	1680
cgtgttcgga	ctgtcagcgc	aggggcgcgc	ggttcttttt	gtcaagaccg	acctgtccgg	1740
tgccctgaat	gaactgcagg	acgaggcagc	gcggctatcg	tggctggcca	cgacgggcgt	1800
tccttgcgca	gctgtgctcg	acgttgctac	tgaagcggga	agggactggc	tgctattggg	1860
cgaagtgccg	gggcaggatc	tcctgtcatc	tcaccttgct	cctgccgaga	aagtatccat	1920
catggctgat	gcaatgcggc	ggctgcatac	gcttgatccg	gtacctgcc	cattcgacca	1980
ccaagcgaaa	catcgcatcg	agcgagcacg	tactcggatg	gaagccggtc	ttgtcgatca	2040
ggatgatctg	gacgaagagc	atcaggggct	cgcgccagcc	gaactgttcg	ccaggctcaa	2100
ggcgcgcgat	cccgcggcgc	aggatctcgt	cgtgacctat	ggcgatgcct	gcttgccgaa	2160

16/27

tatcatggtg	gaaaatggcc	gcttttctgg	attcatcgac	tgtggccggc	tgggtgtggc	2220
ggaccgctat	caggacatag	cgttggctac	ccgtgatatt	gctgaagagc	ttggcggcga	2280
atgggctgac	cgcttctctg	tgctttacgg	tatcgccgct	cccgattcgc	agcgcatcgc	2340
cttctatcgc	cttcttgacg	agttcttctg	agcgggactc	tggggttcga	aatgaccgac	2400
caagcgacgc	ccaacctgcc	atcacgagat	ttcgattcca	ccgccgcctt	ctatgaaagg	2460
ttgggcttcg	gaatcgtttt	ccgggacgcc	ggctggatga	tcctccagcg	cggggatctc	2520
atgctggagt	tcttcgcccc	ccccaaactg	tttattgcag	cttataatgg	ttacaaataa	2580
agcaatagca	tcacaaatth	cacaaataaa	gcattttttt	cactgcattc	tagttgtggt	2640
ttgtccaaac	tcataaatgt	atcttatcat	gtctgtatac	cgtcgacctc	tagctagagc	2700
ttggcgtaat	catggtcata	gctgtttcct	gtgtgaaatt	gttatccgct	cacaattcca	2760
cacaacatac	gagccggaag	cataaagtgt	aaagcctggg	gtgcctaata	agtgaagctaa	2820
ctcacattaa	ttgcgttgcg	ctcactgccc	gctttccagt	cgggaaacct	gtcgtgccag	2880
ctgcattaat	gaatcggcc	acgcgcgggg	agaggcggtt	tgcgtattgg	gcgctcttcc	2940
gcttctctgc	tcactgactc	gctgcgctcg	gtcgttcggc	tgcggcgagc	ggtatcagct	3000
cactcaaagg	cggtaatacg	gttatccaca	gaatcagggg	ataacgcagg	aaagaacatg	3060
tgagcaaaag	gccagcaaaa	ggccaggaac	cgtaaaaagg	ccgcgttgct	ggcgtttttc	3120
cataggetcc	gccccctga	cgagcatcac	aaaaatcgac	gctcaagtca	gaggtggcga	3180
aacccgacag	gactataaag	ataccaggcg	tttccccctg	gaagctccct	cgtgcgctct	3240
cctgttccga	ccctgcccgt	taccggatac	ctgtccgcct	ttctcccttc	gggaagcgtg	3300
gcgctttctc	atagctcacg	ctgtaggtat	ctcagttcgg	tgtaggtcgt	tcgctccaag	3360
ctgggctgtg	tgcacgaacc	ccccgttcag	cccgaccgct	gcgccttata	cggtaactat	3420
cgtcttgagt	ccaacccggt	aagacacgac	ttatcgccac	tggcagcagc	cactggtaac	3480
aggattagca	gagcgaggta	tgtaggcggt	gctacagagt	tcttgaagtg	gtggcctaac	3540
tacggctaca	ctagaagaac	agtatttggg	atctgcgctc	tgtgaagcc	agttaccttc	3600
ggaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	ccgctggtag	cggttttttt	3660
gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	3720
tctacggggg	ctgacgctca	gtggaacgaa	aactcacgtt	aagggattht	ggtcatgaga	3780
ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagtht	taaatcaatc	3840
taaagtatat	atgagtaaac	ttggctctgac	agttaccaat	gcttaatcag	tgaggcacct	3900
atctcagcga	tctgtctatt	tcgttcatcc	atagttgcct	gactccccgt	cgtgtagata	3960
actacgatac	gggagggttt	accatctggc	cccagtgctg	caatgatacc	gcgagacca	4020
cgtcacccgg	ctccagattt	atcagcaata	aaccagccag	ccggaagggc	cgagcgcaga	4080
agtggctctg	caactttata	cgcctccatc	cagtctatta	attgttgccg	ggaagctaga	4140
gtaagtagtt	cgccagttaa	tagtttgccg	aacgttgtht	ccattgctac	aggcatcgtg	4200
gtgtcacgct	cgtcgthtgg	tatggcttca	ttcagctccg	gttcccaacg	atcaaggcga	4260
gttacatgat	ccccatgttt	gtgcaaaaaa	gcggttagct	ccttcggthc	tccgatcgtt	4320
gtcagaagta	agttggccgc	agtgttatca	ctcatggtht	tggcagcact	gcataattct	4380
cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtactc	aaccaagtca	4440
ttctgagaat	agtgtatgcg	gcgaccgagt	tgtctthtgc	cggcgtcaat	acgggataat	4500
accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacgttc	ttcggggcga	4560
aaactctcaa	ggatcttacc	gctgttgaga	tccagthtca	tgtaaccac	tcgtgcaccc	4620
aactgatctt	cagcatcttt	tactthtacc	agcgtthtctg	ggtgagcaaa	aacaggaagg	4680
caaatgccc	caaaaaagg	aataagggcg	acacggaaat	gttgaatact	catactcttc	4740



17/27

ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt 4800  
gaatgtattt agaaaaataa acaaataagg gttccgcgca catttccccg aaaagtgcc 4860  
cctgacgtc 4869

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized primer sequence

<400> 34  
ggggatcagc gtttgagtaa 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized primer sequence

<400> 35  
taggccccac ctccttctat 20

<210> 36  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized primer sequence

<400> 36  
tgcgatcca gagcagattg tactgagagt 30

<210> 37  
<211> 29

18/27

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized primer sequence

&lt;400&gt; 37

ctctatctcg agtgaggcgg aaagaacca

29

&lt;210&gt; 38

&lt;211&gt; 40

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized primer sequence

&lt;400&gt; 38

tttaagcttg aagactatatt ttacatcagg ttgtttttct

40

&lt;210&gt; 39

&lt;211&gt; 37

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized primer sequence

&lt;400&gt; 39

tttaagcttg aagacacggt gtttcgtcct ttccaca

37

&lt;210&gt; 40

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized double-stranded oligonucleotide sequence

19/27

&lt;400&gt; 40

caccgaagca gcacgacttc ttcttcaaga gagaagaagt cgtgctgctt c

51

&lt;210&gt; 41

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized double-stranded oligonucleotide sequence

&lt;400&gt; 41

aaaagaagca gcacgacttc ttctctcttg aagaagaagt cgtgctgctt c

51

&lt;210&gt; 42

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized primer sequence

&lt;400&gt; 42

ggggtaccag gatggagccg ctgaaggtgg

30

&lt;210&gt; 43

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized primer sequence

&lt;400&gt; 43

gggaattctt aggatgctct gatgttggcg tcg

33

&lt;210&gt; 44

&lt;211&gt; 51

20/27

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 44

aaacttatgg atggagcacc tttcaagaga aggtgctcca tccataagtt t

51

&lt;210&gt; 45

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 45

aatcagagaa gctttactca tttcaagaga atgagtaaag cttctctgat t

51

&lt;210&gt; 46

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 46

aacaactga ctgaagataa gttcaagaga cttatcttca gtcagtttgt t

51

&lt;210&gt; 47

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 47

21/27

aactcgtaat gacatttcaa cttcaagaga gttgaaatgt cattacgagt t 51

<210> 48  
<211> 51  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized hairpin siRNA sequence

<400> 48  
aaaagtgatc tgcaactcctt tttcaagaga aaagagttgc agatcacttt t 51

<210> 49  
<211> 51  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized hairpin siRNA sequence

<400> 49  
aagtgatctg caactctttc attcaagaga tgaaagagtt gcagatcact t 51

<210> 50  
<211> 51  
<212> DNA  
<213> Artificial

<220>  
<223> An artificially synthesized hairpin siRNA sequence

<400> 50  
aactctttca ccatctgtaa tttcaagaga attacagatg gtgaaagagt t 51

<210> 51  
<211> 51  
<212> DNA  
<213> Artificial



22/27

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 51

aactgttcga ttgtgttcaa tttcaagaga attgaacaca atcgaacagt t

51

&lt;210&gt; 52

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 52

aaggatgctg atatgctaac tttcaagaga agttagcata tcagcatcct t

51

&lt;210&gt; 53

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 53

aactggtgat gagcaagtat gttcaagaga catacttgct catcaccagt t

51

&lt;210&gt; 54

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized hairpin siRNA sequence

&lt;400&gt; 54

aagtatggaa ggaagttcaa gttcaagaga cttgaacttc cttccatact t

51

23/27

<210> 55  
<211> 51  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized hairpin siRNA sequence

<400> 55

aacatctacc agctgaaggt gttcaagaga caccttcagc tggtagatgt t 51

<210> 56  
<211> 51  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized hairpin siRNA sequence

<400> 56

aagcaatgaa gaatctgaga cttcaagaga gtctcagatt cttcattgct t 51

<210> 57  
<211> 21  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 57

aaacttatgg atggagcacc t 21

<210> 58  
<211> 21  
<212> DNA  
<213> Artificial

<220>

24/27

<223> An artificially synthesized target sequence for siRNA

<400> 58

aatcagagaa gctttactca t

21

<210> 59

<211> 21

<212> DNA

<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 59

aacaaactga ctgaagataa g

21

<210> 60

<211> 21

<212> DNA

<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 60

aactcgtaat gacatttcaa c

21

<210> 61

<211> 21

<212> DNA

<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 61

aaaagtgatc tgcaactett t

21

<210> 62

25/27

<211> 21  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 62

aagtgatctg caactctttc a

21

<210> 63  
<211> 21  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 63

aactctttca ccatctgtaa t

21

<210> 64  
<211> 21  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 64

aactgttcga ttgtgttcaa t

21

<210> 65  
<211> 21  
<212> DNA  
<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

26/27

&lt;400&gt; 65

aaggatgctg atatgctaac t

21

&lt;210&gt; 66

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized target sequence for siRNA

&lt;400&gt; 66

aactggtgat gagcaagtat g

21

&lt;210&gt; 67

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized target sequence for siRNA

&lt;400&gt; 67

aagtatggaa ggaagttcaa g

21

&lt;210&gt; 68

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; An artificially synthesized target sequence for siRNA

&lt;400&gt; 68

aacatctacc agctgaaggt g

21

&lt;210&gt; 69

&lt;211&gt; 21

&lt;212&gt; DNA

27/27

<213> Artificial

<220>

<223> An artificially synthesized target sequence for siRNA

<400> 69

aagcaatgaa gaatctgaga c

21